Breast cancer biomarkers, and a new clinical category for HER2 expression

Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients

Frontiers HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study

POR Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer

MLO LABline Daily - Feb 22nd, 2024

Determining breast cancer biomarker status and associated morphological features using deep learning

Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer - Computational and Structural Biotechnology Journal

HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

Pathology Report, Pathologist Melbourne, VIC

Identification of long-term survival-associated gene in breast cancer

HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort - Modern Pathology

Breast cancer biomarkers

Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study